Related Experiment Video
Updated: May 22, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Hepsin in the diagnosis of prostate cancer
G Pace1, R Pomante, C Vicentini
1Department of Health Sciences, University of L'Aquila, L'Aquila, Italy. giannapace@gmail.com
Aim:
In the current study we verified whether the expression of hepsin in prostate cancer (PCa) of samples obtained from radical retropubic prostatectomies (RRP) was significantly different from the adjacent normal prostatic tissue. METHODS. We evaluate the expression of hepsin by using immunohistochemistry in PCa tissue in respect to the adjacent normal tissue, of 18 patients who underwent RRP.
Results:
Hepsin positive immunoreactivity was estimated on the staining intensity as negative (0), weakly positive (1+), moderately positive (2+), and strongly positive (3+). Hepsin immunoreactivity was detected in 100.0% PCa: 94.4% of cases showed a moderate/strong intensity, 5.6% a weak intensity. The adjacent benign prostatic tissue demonstrated a 83.3% of weak intensity, 11.1% had no reactivity and 5.6% were moderately intense. PCa demonstrated a significant higher (P<0.05) hepsin intensity (2.67) than the adjacent benign tissue (0.94).
Conclusion:
Hepsin should be regarded as a novel potential immunohistochemical marker for the histopathological diagnosis of PCa.
